http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103937808-B
Outgoing Links
Predicate | Object |
---|---|
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2014-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-103937808-B |
titleOfInvention | Expression method and anti-tumor application of recombinant bombyxins |
abstract | The present invention discloses an expression method and an anti-tumor application of recombinant bombyxins, and belongs to the technical field of gene engineering. The method comprises: according to an expression system, carrying out codon preference optimization on a target gene; adopting a complete gene synthesis technology to synthesize optimized bombyxin gene; linking the gene to an expression vector to construct a recombinant expression vector; transforming the recombinant expression vector into a corresponding expression system; and carrying out further culture, screening and identification to obtain the recombinant expression vector-containing strain, and carrying out induced expression to obtain the target protein. According to the present invention, the recombinant bombyxin II, the recombinant bombyxin IV and the mixture of the recombinant bombyxin II and the recombinant bombyxin IV have characteristics of broad antitumor activity and no biological toxicity, and can be used for preparation of anti-tumor drugs. |
priorityDate | 2014-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 103.